Biochemical Sensors for Personalized Therapy in Parkinson’s Disease: Where We Stand
Davide Ciarrocchi, Pasquale Maria Pecoraro, Alessandro Zompanti, Giorgio Pennazza, Marco Santonico, Lazzaro di Biase, Umberto Aguglia · 2024
Read Biochemical Sensors for Personalized Therapy in Parkinson’s Disease: Where We Stand by Davide Ciarrocchi, Pasquale Maria Pecoraro, Alessandro Zompanti, Giorgio Pennazza, Marco Santonico, Lazzaro di Biase, Umberto Aguglia (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11641839.txt.
Description
Davide Ciarrocchi, Lazzaro di Biase, Umberto Aguglia and their co-authors review sensors that track levodopa in Parkinson's disease in 2024. Levodopa is still the main drug for the disease, but as illness advances its good window shrinks and dose timing gets hard.
The review covers ways to sense the drug and related compounds in body fluids like sweat. Methods range from lab cells and point-of-care tools to wearables that use tiny needles or pull fluid through skin. New materials such as graphene have sharpened these sensors. The goal is steady, real-time feedback that could one day guide closed-loop dosing.
Catalog record
| CREATOR | Davide Ciarrocchi, Pasquale Maria Pecoraro, Alessandro Zompanti, Giorgio Pennazza, Marco Santonico, Lazzaro di Biase, Umberto Aguglia |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 72 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |